The effects of clopamide, pindolol and its combination on plasma lipids in 49 hypertensive patients (WHO I-II), divided into three parallel randomized groups, were studied over a 6 months period. Total cholesterol, triglycerides, HDL and LDLcholesterol fractions were determined twice during an initial 4-week washout phase, and after a 1-, 3- and 6-month active hypotensive drug phase. Patients were instructed to maintain their usual dietary habits. Daily drug doses were adjusted progressively to attain optimal hypotensive effects. In the clopamide monotherapy group, total cholesterol increased significantly (p < 0.05); triglycerides and LDL showed a tendency to increase while for HDL a tendency to decrease was observed. In the pindolol monotherapy group, a significant reduction of triglycerides (p < 0.01) and a significant increase of HDL cholesterol (p < 0.05) were recorded. No significant changes in total cholesterol or LDL fraction were observed. Combined pindolol-clopamide therapy decreased total triglycerides (NS), increased HDL significantly (p < 0.05) and did not influence total cholesterol and LDLfraction. It is concluded that pindolol does not negatively influence blood lipids as the thiazide-type diuretic clopamide does, and that when both drugs are used together, the beta-blocker can probably counterbalance the diuretic-induced negative effects on blood lipids. Accordingly, it is suggested that pindolol could be a more favorable beta-blocker drug to be used on hypertensive subjects with metabolic coronary risk factors.